
Your Feed
BETA What are social determinants of health?
BETA what disparities exists in access to myeloma care and novel treatments?
BETA - In addition to your myeloma specialist what other healthcare professionals should you consider adding to your healthcare team?
CARTITUDE-4 Cilta-Cel Efficacy in Myeloma | Binod Dhakal, MD | ASCO 2023

CAR-T and Bi-specific Experiences of PCL Patients
CAR-T Therapy, CARTITUDE-1 Ciltacabtagene Autoleucel in RRMM Patients | Yi Lin, MD, PhD | ASCO 2023
Worldwide Drug Toxicity Trends for MM | Shahzad Raza, MD & Majid Jaberi-Douraki, PhD | ASCO 2023
Phase 1 Therapy PHE885 BCMA-Directed CAR-T Cell Therapy for RRMM | Adam Sperling, MD, PhD | ASCO 2023
DREAMM-3 - Blenrep (Belmaf) vs. PomDex for Relapsed/Refratory Myeloma | Katja Weisel, MD | ASCO 2023
Barriers in Accessing Myeloma Care in Special Populations | Shakira Grant, MBBS | ASCO 2023









